Prot# 27955: A Randomized, Multicenter, Two-Arm, 12-Week Phase IIIb Study to Evaluate Quality of Life (QoL) Measures in Subjects with Relapsing Forms of Multiple Sclerosis Who are Transitioning From Rebif (Interferon beta-1a) to Rebif New Formulation (RNF

Project: Research project

Project Details

StatusFinished
Effective start/end date8/1/07 → 8/1/10

Funding

  • EMD Serono, Inc. (27955 - THE RNF "REBIQOL" STUD)